Pharmaceuticals, Biotechnology & Life Sciences

Gilead Sciences posts a strong earnings beat, raises 2026 guidance, and sees analyst upgrades amid robust Biktarvy and Trodelvy growth.

Regeneron’s Rule 144 insider sales on Nov 2, 2026, are routine, yet paired with a strong earnings beat and expanding oncology pipeline, they signal resilient cash flow, low dilution risk and strategic growth potential amid a competitive biopharma la…

Explore how Sartorius Stedim Biotech’s regulatory disclosure reveals a stable share‑capital structure that boosts investor confidence, supports R&D funding, and positions the company for value‑based reimbursement in Europe’s biotech market.

Vertex’s Q3 2026 earnings show steady CF revenue, strategic diversification, and strong capital allocation, positioning it to navigate patent cliffs and grow shareholder value.

Alnylam hires Dr. Siva Sakhamuri as CTO to boost its RNA therapeutic pipeline and scale manufacturing, combining deep CMC expertise with cutting‑edge RNA tech.

AbbVie’s Q3 earnings reveal strong infliximab growth, rising guidance, and new migraine partnership—yet biosimilar pressure and payer shifts pose real risks.

Get the inside scoop on Bayer AG’s Q3 earnings—why it matters for pharma, ag‑chemicals, investors, and the upcoming U.S. midterms.

Pfizer’s strategic focus on value‑based contracts, emerging market growth, and pipeline innovation positions it to navigate patent cliffs and competitive pressures, driving future revenue and investor confidence.

Fresenius partners with WuXi Biologics to add 37 biosimilar candidates, doubling its biopharma pipeline, targeting high‑margin oncology and eye disease, and securing first‑to‑market control for robust ROI.

Regeneron shares hit a 12‑month high after beating earnings, driven by strong sales of COVID‑19 antibody Bebtelix and gene‑editing platform CRISPR‑Rx, signaling robust growth and investor optimism.